Project Grant R37AI194870
Award Date 8/14/26
Completion Date 7/31/31
Dollars Obligated $804K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $297,000 to Texas Biomedical Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on targeting super-enhancers to regulate HIV transcription and latency. The project, identified as R21AI203697, will define molecular mechanisms by which super-enhancer-associated long non-coding RNAs (SE-lncRNAs) regulate HIV transcription and maintain viral latency in...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $828,340 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate HIV-1 transcription reactivation mechanisms in latent reservoir cells. The research explores the role of transcription factors and Tat protein in initiating and sustaining HIV-1 transcription reactivation, using genetic and genomic approaches to examine HIV-1...
- The National Institute of Allergy and Infectious Diseases awarded $194,375 to the University of North Carolina at Chapel Hill on May 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bifunctional molecules targeting HIV latency reversal through BRD4 recruitment to the viral promoter. The research addresses the heterogeneity of the viral reservoir and multiple mechanisms maintaining HIV latency, which single latency reversal agents cannot overcome. The...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $3.204 million on June 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the interaction between TAR RNA and INI1/SMARCB1, a component of the BAF chromatin remodeling complex, and its role in HIV-1 transcriptional regulation and latency reactivation. The research examines how INI1's winged helix DNA-binding domain binds to TAR RNA to facilitate...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of convergent RNA polymerase II transcription in HIV-1 latency and reactivation. The research aims to define how convergent POL II transcription—specifically antisense and downstream forms originating from the 5'-LTR—regulates sense HIV-1 transcription...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $162,000 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the single-cell epigenetic landscape of the HIV-1 reservoir for effective latency reversal. The research will characterize proviral epigenetics—the regulation of transcription at the chromatin level independent of DNA sequence—to understand how latent HIV is established,...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $3.385 million on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the roles of HIV-1-encoded circular RNAs during viral transcription. The research identifies and characterizes circHIV, a novel circular RNA generated by the HIV-1 provirus that enhances HIV-1 transcription. The investigator team has detected circHIV in HIV-1-infected cell models and in samples...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $894,998 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intrinsic CD4 T cell barriers to HIV-1 latency reversal. The research addresses HIV-1 persistence in CD4 T cells despite effective antiretroviral therapy by examining post-transcriptional mechanisms that constrain productive viral gene expression. The investigator will integrate...
- The National Institute of Allergy and Infectious Diseases awarded $427,626 to The Washington University on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify host factors that mediate nuclear retention of unspliced and partially spliced HIV-1 transcripts. The project will determine mechanisms by which intron-containing HIV-1 RNA molecules remain in the nucleus, contrasting with fully spliced viral messenger RNA that readily accesses host nuclear...